Literature DB >> 3529323

Interaction between beta-lactam and other antibiotics.

S E Holm.   

Abstract

The use of antibiotic combinations remains a necessity in certain clinical circumstances but must be approached with care since the drugs combined may prove antagonistic rather than synergistic. A variety of methods involving different principles are used for the evaluation of drug interactions in vitro; each technique has clear advantages and disadvantages. Information from the literature implies that there is generally a reasonable concordance between in vitro and in vivo results with drug combinations but that discordant results are not uncommon. More specifically, in vitro synergy does not always ensure a successful clinical outcome, but lack of synergy often correlates well with a high rate of therapy failure. A greater knowledge of the mechanisms underlying antibiotic interactions should improve the accuracy of predictions about the in vivo usefulness and safety of drug combinations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529323     DOI: 10.1093/clinids/8.supplement_3.s305

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  3 in total

1.  The innate growth bistability and fitness landscapes of antibiotic-resistant bacteria.

Authors:  J Barrett Deris; Minsu Kim; Zhongge Zhang; Hiroyuki Okano; Rutger Hermsen; Alexander Groisman; Terence Hwa
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

2.  Clinical and pathological evaluation of sulbactam/ampicillin for treatment of experimental bovine pneumonic pasteurellosis.

Authors:  G A Gifford; A A Potter; L A Babiuk
Journal:  Can Vet J       Date:  1988-02       Impact factor: 1.008

3.  When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition.

Authors:  Rafael Pena-Miller; David Laehnemann; Gunther Jansen; Ayari Fuentes-Hernandez; Philip Rosenstiel; Hinrich Schulenburg; Robert Beardmore
Journal:  PLoS Biol       Date:  2013-04-23       Impact factor: 8.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.